Cretaceous Amber Deposits Reveal Large-Scale Tsunamis

Amber concentration in deep-sea sediments.
Traces of tsunamis are hard to identify in the fossil record. Tsunami deposits along a coast are washed away or can be confused with other high-energy events, such as storms.
In a new study, Aya Kubota and colleagues from the Geological Survey of Japan and Chuo University analyzed an extraordinarily rich amber-concentrated beds found in a quarry on Hokkaido Island in northern Japan. Between the grey layers of sand- and mudstone deposited on the seafloor, the yellow amber — fossil tree resin formed typically on land — sticks out. Based on radiometric dating of zircon grains preserved in tuff layers interbedded between the mudstone and amber beds, the entire sedimentary succession formed around 116 and 114 million years ago.
So-called flame structures, which form when soft material is folded or flattened before fully hardening, help to explain how the strange amber deposits formed.
Amber layers seen under fluorescent light and daylight show flattening of the single amber ... More fragments, suggesting they were deposited as still soft tree resin.
In the early Cretaceous, while the region was a oceanic basin, large amount of tree resin was rapidly swept out from a nearby coast to the open ocean by the backwash from one or more tsunamis. The tree resin then sank to the seafloor where it was covered by a sediments, deforming the single fragments and preserving them as amber.
Similar concentrations of material originating on land and transported to open waters may be helpful in finding further tsunamis, the researchers conclude.
Most tsunamis are generated by earthquakes, when the seafloor shifts suddenly and displaces a large quantity of water, but they can also be triggered by a landslide, a volcanic eruption or a meteor impact.
Modern databases list more than 2.000 tsunamis in the last 4.000 years. Most of these records are based on historical documents and likely underestimate the real number. Geological evidence can provide a deeper understanding of past extreme events and is critical for hazard preparation and risk assessment now and in the future.
The study,"Neon Isotopes in Geothermal Gases From the Kenya Rift Reveal a Common Deep Mantle Source Beneath East Africa," was published in the journal Geophysical Research Letters.
Additional material provided by the Nature Publishing Group.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

2 hours ago

• Yahoo

PanBrain Tech Unveils Breakthrough Brain-Computer Interface Device at BEYOND EXPO 2025 in Macau

MACAU, June 23, 2025 /PRNewswire/ -- Brain science technology company PanBrain Tech Co., Ltd. drew widespread attention at the BEYOND International Technology Innovation Expo 2025 in Macau with the debut of its flagship brain-computer interface (BCI) device, the PanBrain EC2. The wearable device leverages transcranial direct current stimulation (tDCS) to enhance neuroplasticity, cognitive function, and support overall mental performance. Visitors lined up at the company's booth to try the EC2 for themselves. Many said they had never encountered a product like it before, and reported feeling more focused, energized, and mentally refreshed after a brief session. Unlike common wearables such as smartwatches or headbands that passively track physiological metrics, the PanBrain EC2 actively stimulates the brain's prefrontal cortex using clinically validated tDCS technology. It is designed to support improvements in attention, mood regulation, sleep quality, and mental vitality. "The response at BEYOND Expo was phenomenal," said Dr. Nai-Lin Yao, founder and CEO of PanBrain Tech. "We're thrilled to see such global interest in accessible, brain science-based technologies." Understanding tDCS Technology Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulation technique grounded in decades of clinical research. Widely used in the neurology departments of major hospitals, tDCS delivers a weak direct current to targeted regions of the cerebral cortex. According to the Hebbian principle, this current can reshape synaptic connections between neurons, activate neural circuits, and accelerate the metabolism of excitatory neurotransmitters such as glutamate. Clinical studies have demonstrated that tDCS may enhance memory, attention, and mood, and may also reduce symptoms of anxiety, depression, procrastination, and sleep disturbances. About PanBrain Tech Founded in 2019 by Dr. Nai-Lin Yao, a Yale-trained psychiatrist and postdoctoral researcher, PanBrain Tech is a brain science–driven technology company focused on advancing cognitive health through accessible innovation. The company holds multiple proprietary patents and certifications, and was named a National High-Tech Enterprise in China in 2024, as well as a Specialized and Innovative SME in Shenzhen. As of April 2025, PanBrain has sold more than 12,000 tDCS devices to the global market. PanBrain is currently expanding its global research collaborations in neuroscience and will showcase its technology at the CES 2026 International Consumer Electronics Show in Las Vegas—a major milestone in the company's international growth strategy. For more information, visit Press inquiries: info@ Linkedin: Instagram: View original content to download multimedia: SOURCE PanBrain Tech Co., Ltd.

Yahoo

4 hours ago

• Yahoo

Quanterix Expands Reach with IVD and Large Reference Labs

Simoa Technology Advances Earlier Disease Detection by Measuring Signature Biomarkers BILLERICA, Mass., June 23, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration by the Ministry of Food and Drug Safety (MFDS) in South Korea through its regional distribution partner, HS Biosystems. The continued expansion of the industry-leading Simoa® technology platform into global markets demonstrates a key milestone in broadening validation of biomarker-based testing and providing clinicians with minimally invasive tools that can help enhance diagnostic accuracy and improve accessibility. Through its unparalleled sensitivity and multi-marker testing capability, the Simoa platform delivers ultrasensitive biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ) of traditional measurement platforms. "Quanterix is the only platform in the neurodegenerative space that can be used in research to discover a biomarker, power an endpoint in a clinical trial and progress to a diagnostic test," said Masoud Toloue, Chief Executive Officer at Quanterix. "Other instruments only address narrow use cases, as they are either only high-plex discovery orientated or diagnostic use only. Quanterix makes discovery to diagnostics happen by powering a critical step in between, biopharma clinical trials. As a result, our ultra-sensitive Simoa technology serves as the backbone for many of the Alzheimer's tests coming to the market today." Quanterix has established several new global collaborations with laboratories and patient testing centers, further strengthening the infrastructure for Alzheimer's testing and reinforcing its clinical utility. These recent collaborations include: ARUP Laboratories - a leading national reference laboratory that recently launched a blood test for phosphorylated tau 217 (P-tau217) to assist in identifying whether cognitive decline symptoms in patients ages 60 years and older are related to Alzheimer's disease (AD) pathology. ARUP's test will be performed on Quanterix's SP-X® platform with the Quanterix Simoa® assay kit, which uses P-tau217 antibody technology licensed from Eli Lilly and Company. Neurogen Biomarking – the world's first ecosystem for memory loss with end-to-end patient support recently announced an easy-to-use at-home blood biomarker collection test that can measure phosphorylated tau 217 (P-tau217), a specific marker for Alzheimer's disease pathology and MCI, using Quanterix's highly sensitive technology. NSW Health Pathology – the largest public pathology service in Australia, has validated NfL for patient testing. Rede D'Or, Richet Laboratory (IDOR) – the largest integrated health care network in Brazil, covering over 70 hospitals, was the first Brazilian institution to acquire a Simoa HD-X and implement both P-tau217 and NfL for testing. IDOR recently published their first paper in Nature Communications on their work to reduce the underdiagnosis of AD in Brazil. According to research, early signs of Alzheimer's disease (AD) may begin 20 years or more before symptoms appear. The Simoa platform equips customers with advanced insights to help accelerate their research and diagnosis, along with accelerating early detection during this crucial timeframe, allowing patients expanded access to treatments that are not available once the disease has progressed to an advanced stage. "Our team works primarily on Alzheimer's Disease and dementia, so from day one, our focus has been on reporting how Simoa biomarkers perform when detecting amyloid status and cognitive decline in a local sample," said Luis Eduardo da Silva Santos, Scientist, Rede D'Or Institute for Research and Education. "IDOR was the first Brazilian institution to acquire a Simoa HD-X and we are excited to see that our work, published in Nature Communications, is now serving as the basis for the local implementation of two Simoa kits, P-tau217 ALZpath and NfL. We expect these tests to be more affordable than current alternatives and to contribute to reducing the underdiagnosis of AD in Brazil." For more information on the Simoa platform, visit About QuanterixFrom discovery to diagnostics, Quanterix's ultrasensitive biomarker detection fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. View source version on Contacts Media Contact: Marissa Klaassenmedia@ Investor Relations Contact: Joshua Youngir@

Associated Press

5 hours ago

• Associated Press

Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

OSAKA, Japan & BOSTON--(BUSINESS WIRE)--Jun 23, 2025-- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; 'Ono') and Vertex Pharmaceuticals Incorporated (Headquarters: Boston, MA, U.S.; CEO: Reshma Kewalramani, M.D.; 'Vertex') today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other serious B cell-mediated diseases. Under the terms of the agreement, Ono will pay Vertex an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex's clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications. 'Vertex has a strong track record of developing innovative therapies for serious diseases. Through this strategic partnership, we can strengthen our late-stage pipeline in the immunology field, which is a key focus area for Ono,' said Toichi Takino, Representative Director, President and Chief Operating Officer of Ono. 'We look forward to collaborating with Vertex to provide this new therapeutic option for patients with IgAN and other autoimmune diseases in Japan and South Korea, and to maximize the value of this treatment.' 'Ono is a proven leader in Japan and South Korea, bringing established local relationships, infrastructure, and nephrology expertise that make them a perfect partner for Vertex as we look to deliver povetacicept to the thousands of potential patients in these countries,' said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. 'We are very pleased to partner with Ono and look forward to close collaboration as we continue to advance this potentially best-in-class treatment for IgAN, pMN and other serious B cell-mediated diseases.' The Phase 3 clinical trial is underway in multiple regions, including the U.S., EU and Asia. Specifically, Japanese and South Korean regulatory authorities have approved the Clinical Trial Application (CTA) for RAINIER, where the Phase 3 trial is underway. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. View source version on CONTACT: Ono Pharmaceutical Co., Ltd. Corporate Communications [email protected] more information: Vertex Pharmaceuticals Incorporated Investors: [email protected]: [email protected] or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 KEYWORD: NORTH AMERICA UNITED STATES SOUTH KOREA ASIA PACIFIC JAPAN MASSACHUSETTS INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL CLINICAL TRIALS SOURCE: Ono Pharmaceutical Co., Ltd. Copyright Business Wire 2025. PUB: 06/23/2025 04:00 AM/DISC: 06/23/2025 04:02 AM